Excreted Unchanged %
None
Half-Life (Normalesrd) Hours
1.3-2.9/Unchanged
Plasma Protein Binding %
>98
Volume Of Distribution L/Kg
No data
Dose For Normal Renal Function
15-60 mg q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Karol MD, Machinist JM, Cavanaugh JM. Lansoprazole pharmacokinetics in subjects with various degrees of kidney function. Clin Pharmacol Ther. 1997; 61: 450-8. [PMID: 9129562] / Spencer CM, Faulds D. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs. 1994; 48: 404-30. [PMID: 7527761]